Karyopharm to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (KPTI), a commercial-stage pharmaceutical company focused on innovative cancer therapies, announced its senior management team will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 5, 2025, at 3:10 p.m. ET in New York. Investors can access a live webcast of the presentation with accompanying slides through the 'Events & Presentations' section of Karyopharm's investor relations website. The presentation will also be available for replay after the event.

NEWTON, Mass., June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY.

A live webcast of the presentation along with accompanying slides can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-the-jefferies-global-healthcare-conference-302471316.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm (KPTI) presenting at the Jefferies Global Healthcare Conference?

Karyopharm is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:10 p.m. ET in New York.

How can investors watch Karyopharm's (KPTI) Jefferies conference presentation?

Investors can watch the live webcast and access presentation slides through the 'Events & Presentations' section of Karyopharm's investor website at investors.karyopharm.com/events-presentations.

What type of company is Karyopharm Therapeutics (KPTI)?

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that specializes in developing novel cancer therapies.

Will Karyopharm's (KPTI) Jefferies conference presentation be available for replay?

Yes, the presentation will be available for replay following the event through Karyopharm's investor relations website.